Maximizing Pharmaceutical Patent Life Cycles (877L06.ADV)
Venue: Grand Hyatt San Francisco
|Event Date/Time: Jun 13, 2006||End Date/Time: Jun 14, 2006|
|Early Registration Date: Apr 01, 2006|
However, the MMA and the Final Rule are not the only factors affecting pharmaceutical patents. The heightening political controversy over generic/follow-on biologics ( a huge issue on the West Coast), patent reform, importation, re-importation and counterfeiting may force additional Hatch Waxman amendments.
Other issues include:
-How the interplay of MMA and the Final Rule (as amended) will affect:
-Orange Book listings and challenges
-Paragraph IV Certifications
-Exclusivity: 180 day exclusivity, orphan drug, pediatric and beyond
-The effects of the Integra and Housey decisions on the Hatch Waxman Safe Harbor
-The threat of compulsory licensing to US patents
Counsel to brand name and generic pharmaceutical companies need to constantly stay abreast of these issues. We have held this event on 6 previous occasions in light of this need. This will be our seventh program on this topic and our first West Coast installment.